Final guidance on use of Ajovy published
The National Institute for Health and Care Excellence (NICE) has published its final guidance on fremanezumab (Ajovy). The guidance sets out how the drug can be prescribed in the NHS in England and Wales.
It is an important step towards the availability of it to treat chronic migraine following its approval by NICE in March. Clinical Commissioning Groups in England will now have three months to comply with this recommendation. The NHS in Wales has two months to comply.
NICE has said that the drug should be available for patients living with chronic migraine who have already failed to respond to at least three other migraine preventive drugs. You can read the full guidance on the NICE website.
Patients who think they may be eligible and would benefit from this drug should speak to their NHS clinician about accessing it.
We are delighted to announce that we will be holding a virtual Migraine Trust International Symposium (MTIS) this year. While we have had to go online due to the pandemic, we are very happy that we are still able to hold it this year from 10-13 September.
We are particularly excited about the MTIS Public Day that will take place on Sunday 13 September. We will bring people affected by migraine and the world’s leading researchers together virtually to discuss migraine research and treatments. We are just finalising the programme and will share it and details about registering for a place in the next ebulletin.
Migraine in the media
There was an article in The Guardian about how cluster headaches are often misdiagnosed for migraine.
It was based on a paper co-authored by our trustee, Professor Fayyaz Ahmed, who highlighted the length people with cluster headache often have to wait for a diagnosis, and how “it is around three to four years on average, but for some it may be 20-plus years”.
Ria Bhola, our Headache Nurse Specialist, wrote about the symptoms and stages of a migraine attack for a supplement about pain in The Guardian.